Caribou Biosciences, Inc. Balance Sheet
CRBU|5 years of annual SEC 10-K data (FY2021-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 5 fiscal years. All figures from audited SEC 10-K filings.
Caribou Biosciences, Inc. had $175M in total assets and $122M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $12.4M | $16.3M | $51.2M | $58.3M | $240.4M |
| Accounts Receivable | $69.0K | $265.0K | $148.0K | $202.0K | $1.2M |
| Current Assets | $145.2M | $219.4M | $338.8M | $260.2M | $391.2M |
| PP&E (Net) | $6.8M | $19.3M | $18.3M | $10.7M | $4.9M |
| Total Assets | $175.4M | $313.3M | $432.2M | $373.8M | $442.4M |
| Current Liabilities | $25.4M | $30.7M | $28.3M | $28.1M | $25.8M |
| Shareholders' Equity | $122.2M | $368.4M | $300.9M | $387.8M | -$23.4M |